Cargando…

Correlates and management of comorbid anxiety disorders in schizophrenia

BACKGROUND: Only a few studies have examined the treatability of anxiety disorders in schizophrenia, even though it is generally accepted that in the absence of schizophrenia, the anxiety disorders are safely and effectively treatable. AIM: The aim of this study was to study the relation of anxiety...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiran, Chandra, Chaudhury, Suprakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592206/
https://www.ncbi.nlm.nih.gov/pubmed/31359983
http://dx.doi.org/10.4103/ipj.ipj_66_17
_version_ 1783429861137711104
author Kiran, Chandra
Chaudhury, Suprakash
author_facet Kiran, Chandra
Chaudhury, Suprakash
author_sort Kiran, Chandra
collection PubMed
description BACKGROUND: Only a few studies have examined the treatability of anxiety disorders in schizophrenia, even though it is generally accepted that in the absence of schizophrenia, the anxiety disorders are safely and effectively treatable. AIM: The aim of this study was to study the relation of anxiety disorders with the positive and negative symptoms of schizophrenia and the effect of treatment of different anxiety disorders in schizophrenia patients. MATERIALS AND METHODS: The study was carried out on inpatients of a tertiary care psychiatric hospital using a purposive sampling technique. The schizophrenia patients were evaluated for psychopathology and the presence of anxiety disorder at baseline. After being prescribed with antipsychotic medication in a suitable dose for 8 weeks, they were followed up at monthly intervals for the course of both schizophrenia and anxiety disorders. Thereafter, an selective serotonin reuptake inhibitor (SSRI) was also prescribed to the schizophrenia patients with comorbid anxiety disorder, and the patients were again followed up for a period of 8 weeks to assess the progress of schizophrenia and anxiety disorder. RESULTS: The prevalence of anxiety disorder in 93 schizophrenia patients included in the present study was 45.16%. The most common comorbid anxiety disorders in schizophrenia patients were panic disorder (18.27%), social anxiety disorder (9.68%), obsessive-compulsive disorder (8.60%), and agoraphobia (6.45%). Schizophrenia patients with anxiety disorder had a significantly higher positive score of the Positive and Negative Symptom Scale for Schizophrenia (PANSS) and a significantly lower score on the negative scale and the general psychopathology scale of the PANSS, as compared to the scores of the schizophrenia group without anxiety disorders. Schizophrenia patients with anxiety disorders responded well to the combination of SSRIs and antipsychotics but not antipsychotics alone. CONCLUSIONS: Comorbid anxiety disorders are common in schizophrenia. Schizophrenia patients with anxiety disorders differ significantly from those without anxiety disorders in their basic psychopathology. These anxiety disorders are quite responsive to the SSRIs but not to antipsychotics alone. Further, there is a shorter duration of illness in schizophrenia patients with anxiety disorders as compared to schizophrenia patients without anxiety disorders assigning a prognostic significance to the presence of comorbid anxiety disorders in schizophrenia.
format Online
Article
Text
id pubmed-6592206
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-65922062019-07-29 Correlates and management of comorbid anxiety disorders in schizophrenia Kiran, Chandra Chaudhury, Suprakash Ind Psychiatry J Original Article BACKGROUND: Only a few studies have examined the treatability of anxiety disorders in schizophrenia, even though it is generally accepted that in the absence of schizophrenia, the anxiety disorders are safely and effectively treatable. AIM: The aim of this study was to study the relation of anxiety disorders with the positive and negative symptoms of schizophrenia and the effect of treatment of different anxiety disorders in schizophrenia patients. MATERIALS AND METHODS: The study was carried out on inpatients of a tertiary care psychiatric hospital using a purposive sampling technique. The schizophrenia patients were evaluated for psychopathology and the presence of anxiety disorder at baseline. After being prescribed with antipsychotic medication in a suitable dose for 8 weeks, they were followed up at monthly intervals for the course of both schizophrenia and anxiety disorders. Thereafter, an selective serotonin reuptake inhibitor (SSRI) was also prescribed to the schizophrenia patients with comorbid anxiety disorder, and the patients were again followed up for a period of 8 weeks to assess the progress of schizophrenia and anxiety disorder. RESULTS: The prevalence of anxiety disorder in 93 schizophrenia patients included in the present study was 45.16%. The most common comorbid anxiety disorders in schizophrenia patients were panic disorder (18.27%), social anxiety disorder (9.68%), obsessive-compulsive disorder (8.60%), and agoraphobia (6.45%). Schizophrenia patients with anxiety disorder had a significantly higher positive score of the Positive and Negative Symptom Scale for Schizophrenia (PANSS) and a significantly lower score on the negative scale and the general psychopathology scale of the PANSS, as compared to the scores of the schizophrenia group without anxiety disorders. Schizophrenia patients with anxiety disorders responded well to the combination of SSRIs and antipsychotics but not antipsychotics alone. CONCLUSIONS: Comorbid anxiety disorders are common in schizophrenia. Schizophrenia patients with anxiety disorders differ significantly from those without anxiety disorders in their basic psychopathology. These anxiety disorders are quite responsive to the SSRIs but not to antipsychotics alone. Further, there is a shorter duration of illness in schizophrenia patients with anxiety disorders as compared to schizophrenia patients without anxiety disorders assigning a prognostic significance to the presence of comorbid anxiety disorders in schizophrenia. Wolters Kluwer - Medknow 2018 /pmc/articles/PMC6592206/ /pubmed/31359983 http://dx.doi.org/10.4103/ipj.ipj_66_17 Text en Copyright: © 2019 Industrial Psychiatry Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kiran, Chandra
Chaudhury, Suprakash
Correlates and management of comorbid anxiety disorders in schizophrenia
title Correlates and management of comorbid anxiety disorders in schizophrenia
title_full Correlates and management of comorbid anxiety disorders in schizophrenia
title_fullStr Correlates and management of comorbid anxiety disorders in schizophrenia
title_full_unstemmed Correlates and management of comorbid anxiety disorders in schizophrenia
title_short Correlates and management of comorbid anxiety disorders in schizophrenia
title_sort correlates and management of comorbid anxiety disorders in schizophrenia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592206/
https://www.ncbi.nlm.nih.gov/pubmed/31359983
http://dx.doi.org/10.4103/ipj.ipj_66_17
work_keys_str_mv AT kiranchandra correlatesandmanagementofcomorbidanxietydisordersinschizophrenia
AT chaudhurysuprakash correlatesandmanagementofcomorbidanxietydisordersinschizophrenia